Sheldon L. Koenig

President and CEO at Esperion Therapeutics

Board

Since May 2021

Age

58 years

Education

Holds a Master of Business Administration from Monmouth University and a Bachelor of Applied Science from Drexel University.

Tenure

Joined Esperion as Chief Operating Officer in December 2020 and was promoted to President and Chief Executive Officer in May 2021.

Also at Esperion Therapeutics

Benjamin Halladay

Chief Financial Officer

Benjamin Looker

General Counsel

Eric Warren

Chief Commercial Officer

About

Sheldon L. Koenig has built an extensive career in the pharmaceutical industry with over 25 years of experience, including leadership roles at Merck & Co., Sanofi, and Portola Pharmaceuticals.

At Esperion Therapeutics, he has been instrumental in steering strategic initiatives focused on revenue growth, operating profitability, and portfolio expansion. His efforts have led to the development of innovative therapies and strategic product combinations aimed at addressing preventative cardiovascular care.

His strong academic foundation, underscored by advanced degrees, has enabled him to navigate complex global markets and drive significant advancements in the industry. This blend of strategic vision and operational expertise continues to shape his impactful contributions to the success of Esperion Therapeutics.

$ESPR Performance Under Sheldon L. Koenig

Past Roles

Organization	Role	Date Range	Details
Esperion Therapeutics (ESPR)	Chief Operating Officer	December 2020 - May 2021	Transitioned to President & CEO in May 2021
Portola Pharmaceuticals, Inc.	Executive Vice President and Chief Commercial Officer	January 2019 - August 2020	Served until acquisition by Alexion
Sanofi S.A.	Senior Vice President and Head of the Cardiovascular Franchise	January 2016 - July 2018	Led U.S. business operations and international product launches
Merck & Co., Inc.	Vice President and Global Brand Leader for the Cardiovascular Division	Over 25 years	Held progressively increasing roles and led marketing for the launch of ezetimibe

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$725,000	Annual, 2023	Fixed annual base salary.
All Other Compensation	$16,033	Annual, 2023	Includes 401(k) matching contributions of $15,000 and personal use of company vehicle of $1,033.

Performance Compensation

Data from FY 2023

Non-equity Incentive Plan Compensation

Metric/Component	Weight/Target	Achievement/Result	Additional Details
Execute CVOT presentation, data release, and submissions	40%	100% achieved	Part of Base Corporate Goals.
Achieve US net sales target	25%	100% achieved	Base corporate goal.
Prepare for full-scale commercial launch	10%	100% achieved	Base corporate goal.
Optimize Market Access Environment	10%	100% achieved	Base corporate goal.
Manage cash used in operations to $215MM	10%	100% achieved	Base corporate goal.
Continue to progress pipeline value	5%	100% achieved	Base corporate goal.
Total Base Goals	100%		Summation of base criteria.
Simultaneous publication and presentation of topline data from CVOT by March 31	10%	Achieved	Stretch Goal.
Submit filings to EMA/FDA for cardiovascular risk reduction before July 1	1% per month early; achieved 2%	Achieved	Stretch Goal conditions.
Exceed US net sales target	3%	Achieved	Stretch Goal.
Total Stretch Goals	15%		Summation of stretch criteria.

Overall Achievement: 115% of target.
Target Award Opportunity: 65% of base salary (i.e., 65% of $725,000 = $471,250).
Actual Bonus Payment: $541,938 (calculated as 115% of target bonus).
Evaluation Period: Performance evaluated during 2023 with final payout in December 2023.
Vesting Schedule & Grant Date: Not applicable as the compensation was a cash bonus without equity vesting.